IMTX · Immatics N.V.

Summary

Immatics N.V. announces four oral presentations of clinical data from its PRAME cell therapy and bispecific programs at the 2026 ASCO Annual Meeting.

Key takeaways

• All submitted abstracts selected for oral presentations at 2026 ASCO Annual Meeting (May 29-June 2, Chicago).
• Phase 1b data on anzu-cel in advanced cutaneous and uveal melanoma, focusing on response dynamics.
• Updated Phase 1a/1b data for GEN2 PRAME cell therapy IMA203CD8 in gynecologic cancers at clinically relevant doses.
• Phase 1 data on PRAME cell therapies in synovial sarcoma, expanding beyond melanoma and gynecologic cancers.
• Updated results for MAGEA4/8 bispecific IMA401 across multiple cancers, potential combination with IMA402.